Comparative Pharmacology
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus HYDRO RIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus HYDRO RIDE.
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE vs HYDRO-RIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
None Documented
None Documented
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Terminal half-life 4-6 hours (prolonged in renal impairment).
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic